Literature DB >> 18945681

Differential dependence of hypoxia-inducible factors 1 alpha and 2 alpha on mTORC1 and mTORC2.

Alfredo Toschi1, Evan Lee, Noga Gadir, Michael Ohh, David A Foster.   

Abstract

Constitutive expression of hypoxia-inducible factor (HIF) has been implicated in several proliferative disorders. Constitutive expression of HIF1 alpha and HIF2 alpha has been linked to a number of human cancers, especially renal cell carcinoma (RCC), in which HIF2 alpha expression is the more important contributor. Expression of HIF1 alpha is dependent on the mammalian target of rapamycin (mTOR) and is sensitive to rapamycin. In contrast, there have been no reports linking HIF2 alpha expression with mTOR. mTOR exists in two complexes, mTORC1 and mTORC2, which are differentially sensitive to rapamycin. We report here that although there are clear differences in the sensitivity of HIF1 alpha and HIF2 alpha to rapamycin, both HIF1 alpha and HIF2 alpha expression is dependent on mTOR. HIF1 alpha expression was dependent on both Raptor (a constituent of mTORC1) and Rictor (a constitutive of mTORC2). In contrast, HIF2 alpha was dependent only on the mTORC2 constituent Rictor. These data indicate that although HIF1 alpha is dependent on both mTORC1 and mTORC2, HIF2 alpha is dependent only on mTORC2. We also examined the dependence of HIF alpha expression on the mTORC2 substrate Akt, which exists as three different isoforms, Akt1, Akt2, and Akt3. Interestingly, the expression of HIF2 alpha was dependent on Akt2, whereas that of HIF1 alpha was dependent on Akt3. Because HIF2 alpha is apparently more critical in RCC, this study underscores the importance of targeting mTORC2 and perhaps Akt2 signaling in RCC and other proliferative disorders in which HIF2 alpha has been implicated.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18945681      PMCID: PMC2596400          DOI: 10.1074/jbc.C800170200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  38 in total

Review 1.  Will mTOR inhibitors make it as cancer drugs?

Authors:  Charles L Sawyers
Journal:  Cancer Cell       Date:  2003-11       Impact factor: 31.743

Review 2.  The von Hippel-Lindau tumor suppressor protein and clear cell renal carcinoma.

Authors:  William G Kaelin
Journal:  Clin Cancer Res       Date:  2007-01-15       Impact factor: 12.531

3.  Rapamycin derivatives reduce mTORC2 signaling and inhibit AKT activation in AML.

Authors:  Zhihong Zeng; Dos D Sarbassov; Ismael J Samudio; Karen W L Yee; Mark F Munsell; C Ellen Jackson; Francis J Giles; David M Sabatini; Michael Andreeff; Marina Konopleva
Journal:  Blood       Date:  2006-12-19       Impact factor: 22.113

Review 4.  HIF-1 and mechanisms of hypoxia sensing.

Authors:  G L Semenza
Journal:  Curr Opin Cell Biol       Date:  2001-04       Impact factor: 8.382

5.  Regulation of hypoxia-inducible factor 1alpha expression and function by the mammalian target of rapamycin.

Authors:  Christine C Hudson; Mei Liu; Gary G Chiang; Diane M Otterness; Dawn C Loomis; Fiona Kaper; Amato J Giaccia; Robert T Abraham
Journal:  Mol Cell Biol       Date:  2002-10       Impact factor: 4.272

Review 6.  Von Hippel-Lindau tumor suppressor protein and hypoxia-inducible factor in kidney cancer.

Authors:  Mindy A Maynard; Michael Ohh
Journal:  Am J Nephrol       Date:  2003-12-03       Impact factor: 3.754

7.  Phospholipase D confers rapamycin resistance in human breast cancer cells.

Authors:  Yuhong Chen; Yang Zheng; David A Foster
Journal:  Oncogene       Date:  2003-06-19       Impact factor: 9.867

8.  Inhibition of HIF is necessary for tumor suppression by the von Hippel-Lindau protein.

Authors:  Keiichi Kondo; Jeff Klco; Eijiro Nakamura; Mirna Lechpammer; William G Kaelin
Journal:  Cancer Cell       Date:  2002-04       Impact factor: 31.743

Review 9.  AKT/PKB signaling: navigating downstream.

Authors:  Brendan D Manning; Lewis C Cantley
Journal:  Cell       Date:  2007-06-29       Impact factor: 41.582

Review 10.  Hypoxia-inducible factors: central regulators of the tumor phenotype.

Authors:  John D Gordan; M Celeste Simon
Journal:  Curr Opin Genet Dev       Date:  2007-01-08       Impact factor: 5.578

View more
  140 in total

1.  FM19G11 reverses endothelial dysfunction in rat and human arteries through stimulation of the PI3K/Akt/eNOS pathway, independently of mTOR/HIF-1α activation.

Authors:  M El Assar; J M Sánchez-Puelles; I Royo; E López-Hernández; A Sánchez-Ferrer; J L Aceña; L Rodríguez-Mañas; J Angulo
Journal:  Br J Pharmacol       Date:  2015-01-12       Impact factor: 8.739

2.  Phospholipase D stabilizes HDM2 through an mTORC2/SGK1 pathway.

Authors:  Donggon Lyo; Limei Xu; David A Foster
Journal:  Biochem Biophys Res Commun       Date:  2010-05-08       Impact factor: 3.575

3.  Glycerolipid signals alter mTOR complex 2 (mTORC2) to diminish insulin signaling.

Authors:  Chongben Zhang; Angela A Wendel; Matthew R Keogh; Thurl E Harris; Jie Chen; Rosalind A Coleman
Journal:  Proc Natl Acad Sci U S A       Date:  2012-01-17       Impact factor: 11.205

Review 4.  Strategies to overcome therapeutic resistance in renal cell carcinoma.

Authors:  Peter J Siska; Kathryn E Beckermann; W Kimryn Rathmell; Scott M Haake
Journal:  Urol Oncol       Date:  2017-01-11       Impact factor: 3.498

Review 5.  Oncogenes strike a balance between cellular growth and homeostasis.

Authors:  Bo Qiu; M Celeste Simon
Journal:  Semin Cell Dev Biol       Date:  2015-08-13       Impact factor: 7.727

6.  Rapamycin Protects Spiral Ganglion Neurons from Gentamicin-Induced Degeneration In Vitro.

Authors:  Shasha Guo; Nana Xu; Peng Chen; Ying Liu; Xiaofei Qi; Sheng Liu; Cuixian Li; Jie Tang
Journal:  J Assoc Res Otolaryngol       Date:  2019-06-24

Review 7.  Phosphatidic acid signaling to mTOR: signals for the survival of human cancer cells.

Authors:  David A Foster
Journal:  Biochim Biophys Acta       Date:  2009-03-02

Review 8.  mTOR activation is a biomarker and a central pathway to autoimmune disorders, cancer, obesity, and aging.

Authors:  Andras Perl
Journal:  Ann N Y Acad Sci       Date:  2015-04-23       Impact factor: 5.691

Review 9.  Current and future therapeutic approaches for metastatic pheochromocytoma and paraganglioma: focus on SDHB tumors.

Authors:  J Matro; A Giubellino; K Pacak
Journal:  Horm Metab Res       Date:  2013-01-15       Impact factor: 2.936

10.  Influence of glucosamine on glomerular mesangial cell turnover: implications for hyperglycemia and hexosamine pathway flux.

Authors:  Leighton R James; Catherine Le; James W Scholey
Journal:  Am J Physiol Endocrinol Metab       Date:  2009-11-10       Impact factor: 4.310

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.